Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REPLIGEN CORPORATION

(RGEN)
  Report
Delayed Quote. Delayed Nasdaq - 12/03 04:00:00 pm
262.88 USD   -2.21%
11/22INSIDER SELL : Repligen
MT
11/17REPLIGEN CORPORATION : Technically solid
11/15INSIDER SELL : Repligen
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Repligen Corporation and Navigo GmbH Announce Launch of Industry-FirstáProtein A Ligand for Purification of pH Sensitive Antibodies

09/09/2021 | 07:30am EST

Repligen Corporation and Navigo Proteins GmbH announced they have completed development and validation of a novel protein A ligand that overcomes challenges associated with the purification of pH sensitive antibodies and Fc-fusion proteins. Named NGL-Impact® A Hi pH, the new ligand is the first to address antibody aggregation in low pH elution buffers. While developed specifically to address pH sensitive antibodies and Fc-fusion proteins, NGL-Impact A Hi pH ligand demonstrates high performance for all antibodies, and can be considered for “platform” use due to its broad pH operating range. Protein A affinity ligands are the critical component of Protein A chromatography media that enable the affinity purification of monoclonal antibody-based biologic drugs. There are currently more than 120 monoclonal antibodies and Fc-fusion proteins that have received U.S. FDA regulatory approval and more than 600 are at various stages of clinical development.


ę S&P Capital IQ 2021
All news about REPLIGEN CORPORATION
11/22INSIDER SELL : Repligen
MT
11/15INSIDER SELL : Repligen
MT
11/12Repligen Corporation to Present at Upcoming Investor Conferences
GL
11/08Repligen Releases Inaugural Sustainability Report
AQ
11/05Repligen Releases Inaugural Sustainability Report
AQ
11/04INSIDER SELL : Repligen
MT
11/02INSIDER SELL : Repligen
MT
10/29SVB Leerink Adjusts Price Target on Repligen to $325 from $260, Keeps Outperform Rating
MT
10/28REPLIGEN CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
10/28Repligen Corporation Reports Earnings Results for the Third Quarter and Nine Months End..
CI
More news
Analyst Recommendations on REPLIGEN CORPORATION
More recommendations
Financials (USD)
Sales 2021 664 M - -
Net income 2021 128 M - -
Net cash 2021 431 M - -
P/E ratio 2021 117x
Yield 2021 -
Capitalization 14 534 M 14 534 M -
EV / Sales 2021 21,2x
EV / Sales 2022 17,7x
Nbr of Employees -
Free-Float 93,2%
Chart REPLIGEN CORPORATION
Duration : Period :
Repligen Corporation Technical Analysis Chart | RGEN | US7599161095 | MarketScreener
Technical analysis trends REPLIGEN CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 262,88 $
Average target price 318,11 $
Spread / Average Target 21,0%
EPS Revisions
Managers and Directors
Tony J. Hunt President, Chief Executive Officer & Director
Jon K. Snodgres Chief Financial Officer
Karen A. Dawes Chairman
Ralf Kuriyel Senior Vice President-Research & Development
James R. Bylund Senior Vice President-Global Operations & IT
Sector and Competitors
1st jan.Capi. (M$)
REPLIGEN CORPORATION40.28%14 534
ABBOTT LABORATORIES18.98%230 355
MEDTRONIC PLC-8.77%143 693
BECTON, DICKINSON AND COMPANY-3.42%69 336
HOYA CORPORATION28.35%59 756
DEXCOM, INC.40.51%50 350